

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SR Medical
春雨医疗

SR MEDICAL TECHNOLOGY COMPANY LIMITED

春雨醫療科技有限公司

(formerly known as GR Life Style Company Limited 國銳生活有限公司)

(Incorporated in Hong Kong with limited liability)

(Stock Code: 108)

APPOINTMENT OF DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of SR Medical Technology Company Limited (the “**Company**”) hereby announces that Mr. Shao Jiyong (“**Mr. Shao**”) was nominated as an executive Director, with effect from 16 September 2026.

Biographical details of Mr. Shao are set out below:

Mr. Shao, aged 55, has been appointed as an executive Director, with effect from 16 September 2026. Mr. Shao graduated from Central South University of Technology (now Central South University) with a bachelor’s degree in engineering. He is a professor-level senior engineer and a first-class registered constructor. Mr. Shao has extensive experience in the construction industry and corporate management and is currently the chairman of BCEG Road and Bridge Construction Group Co., Ltd.

As at the date of this announcement, Mr. Shao has entered into a letter of appointment with the Company for an initial fixed term of three years commencing from 16 September 2026, which may be terminated by either party serving on the other not less than three months’ written notice, subject to retirement by rotation and re-election at least once every three years in accordance with the articles of association of the Company and the Listing Rules. Mr. Shao is entitled to an annual directors’ fee of HK\$540,000, which is determined by the Board based on the recommendation of the remuneration committee of the Company, with reference to his experience, his duties and responsibilities in the Company as well as the prevailing market conditions.

As at the date of this announcement, save as disclosed herein, Mr. Shao has not held any directorship in any other listed companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years. Mr. Shao also does not hold any other position with the Company or other members of the Group, nor does he have any other relationship with any Director, senior management, substantial shareholder or controlling shareholder (as defined under the Listing Rules) of the Company. As at the date of this announcement, Mr. Shao holds 2,656,000 shares of the Company, within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), representing approximately 0.08% of the total issued shares of the Company.

Save as disclosed herein, there is no matter relating to the appointment of Mr. Shao that needs to be brought to the attention of the shareholders of the Company, nor is there any information required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board would like to take this opportunity to welcome Mr. Shao in joining the Company.

By order of the Board
SR Medical Technology Company Limited
Wei Chunxian
Chairman

Hong Kong, 16 September 2026

As at the date of this announcement, the executive directors of the Company are Mr. Wei Chunxian, Mr. Wei Laier, Mr. Sun Zhongmin, Mr. Chen Henan, Mr. Liu Bingyang and Mr. Shao Jiyong; and the independent non-executive directors of the Company are Mr. Tung Woon Cheung Eric, Ms. To Tsz Wan Vivien and Mr. Huang Yining.